TriSalus Life Sciences, Inc. TLSI
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) is an oncology medical device company. Its next catalyst on record is nelitolimod: Consolidated clinical update and start of pharma partnering discussions (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: nelitolimod — Consolidated clinical update and start of pharma partnering discussions (H2 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| nelitolimod (TLR9 agonist) | liver and pancreatic cancers (delivered via PEDD) | oligonucleotide-other | Phase 1 |
| TriNav Infusion System family (TriNav, LV, FLX, XP) | liver tumors; thyroid, uterine and genicular artery embolization | device-combination | NA_NON_THERAPEUTIC |
| PRVI (Pancreatic Retrograde Venous Infusion device) | pancreatic tumors | device-combination | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.